Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Massachussetts General Hospital
mi
from
Boston, MA
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Massachussetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
NYU School of Medicine
mi
from
New York, NY
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Sisters of Charity Hospital, Buffalo
mi
from
Williamsville, NY
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Sisters of Charity Hospital, Buffalo
mi
from
Williamsville, NY
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Research Institute of Dallas
mi
from
Dallas, TX
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Research Institute of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
Phase I Clinical Trial Using Topical Silicon Phthalocyanine (Pc 4) Photodynamic Therapy (PDT) for the Treatment of Pre-Malignant and Malignant Skin Conditions
Status: Enrolling
Updated:  12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
Phase I Clinical Trial Using Topical Silicon Phthalocyanine (Pc 4) Photodynamic Therapy (PDT) for the Treatment of Pre-Malignant and Malignant Skin Conditions
Status: Enrolling
Updated: 12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
A Phase II Study of Vorinostat in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
A Phase II Study of Vorinostat in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
A Phase II Study of Vorinostat in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Rockledge, PA
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
A Phase II Study of Vorinostat in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Rockledge, PA
Click here to add this to my saved trials
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
A Phase II Study of Vorinostat in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Juravinski Cancer Centre at Hamilton Health Sciences
mi
from
Hamilton,
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
A Phase II Study of Vorinostat in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Juravinski Cancer Centre at Hamilton Health Sciences
mi
from
Hamilton,
Click here to add this to my saved trials
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
A Prospective, Multicenter, Randomized, Open-label, Active Controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit
Status: Enrolling
Updated:  12/31/1969
Blumenthal Cancer Centre
mi
from
Charlotte, NC
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
A Prospective, Multicenter, Randomized, Open-label, Active Controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit
Status: Enrolling
Updated: 12/31/1969
Blumenthal Cancer Centre
mi
from
Charlotte, NC
Click here to add this to my saved trials
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
A Prospective, Multicenter, Randomized, Open-label, Active Controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit
Status: Enrolling
Updated:  12/31/1969
University Hospital Hradec Králové
mi
from
Hradec Králové,
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
A Prospective, Multicenter, Randomized, Open-label, Active Controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit
Status: Enrolling
Updated: 12/31/1969
University Hospital Hradec Králové
mi
from
Hradec Králové,
Click here to add this to my saved trials
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
mi
from
Montclair, NJ
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
mi
from
Montclair, NJ
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Burke Pharmaceuticals
mi
from
Hot Springs, AR
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Burke Pharmaceuticals
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Colorado Medical Research Center
mi
from
Denver, CO
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Colorado Medical Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Dermatology Associates and Research
mi
from
Coral Gables, FL
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Dermatology Associates and Research
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Gwinnett Clinical Research
mi
from
Snellville, GA
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Gwinnett Clinical Research
mi
from
Snellville, GA
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Scott D. Glazer, M.D., S.C.
mi
from
Buffalo Grove, IL
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Scott D. Glazer, M.D., S.C.
mi
from
Buffalo Grove, IL
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Christie Clinic
mi
from
Champaign, IL
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Christie Clinic
mi
from
Champaign, IL
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Long Island Skin Cancer and Dermatologic Surgery
mi
from
Smithtown, NY
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Long Island Skin Cancer and Dermatologic Surgery
mi
from
Smithtown, NY
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Oregon Dermatology & Research Center
mi
from
Portland, OR
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Oregon Dermatology & Research Center
mi
from
Portland, OR
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
The Education and Research Foundation, Inc.
mi
from
Lynchburg, VA
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
The Education and Research Foundation, Inc.
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Mobile Devices as Educational Skin History Tools
Evaluating the Use of Mobile Devices as Educational Tools Regarding Skin History
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Mobile Devices as Educational Skin History Tools
Evaluating the Use of Mobile Devices as Educational Tools Regarding Skin History
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Fort Smith, AR
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Comprehensive Cancer Center
mi
from
Berkeley, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Comprehensive Cancer Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Peninsula Medical Center
mi
from
Burlingame, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Peninsula Medical Center
mi
from
Burlingame, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Southern California Permanente Medical Group
mi
from
Downey, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Fremont
mi
from
Fremont, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Marin Cancer Institute at Marin General Hospital
mi
from
Greenbrae, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Marin Cancer Institute at Marin General Hospital
mi
from
Greenbrae, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Cancer Institute at Loma Linda University Medical Center
mi
from
Loma Linda, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Cancer Institute at Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Oakland
mi
from
Oakland, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - Palo Alto
mi
from
Palo Alto, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - Palo Alto
mi
from
Palo Alto, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
Click here to add this to my saved trials
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials